Premium
How we approach Philadelphia chromosome‐positive acute lymphoblastic leukemia in children and young adults
Author(s) -
Slayton William B.,
Schultz Kirk R.,
Silverman Lewis B.,
Hunger Stephen P.
Publication year - 2020
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.28543
Subject(s) - medicine , dasatinib , imatinib , lymphoblastic leukemia , philadelphia chromosome , oncology , tyrosine kinase inhibitor , chemotherapy , hematopoietic stem cell transplantation , leukemia , disease , chromosomal translocation , cancer , gene , genetics , myeloid leukemia , biology
Treatment for children with Philadelphia chromosome‐positive acute lymphoblastic leukemia has changed radically over the past 20 years. This type of leukemia used to have dismal prognosis, but today cure rates have improved with combination of cytotoxic chemotherapy and a tyrosine kinase inhibitor such as imatinib or dasatinib, with hematopoietic stem cell transplant reserved for patients who are at high risk based on slow response to therapy or who relapse. Treating these patients can be challenging particularly if they are not enrolled on a clinical trial. Here, we describe our approach to these patients.